Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurodegenerative Disorders {Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Psychotic Disorders, Anxiety Disorders, Trauma, Mood Disord

Central Nervous System Disorders Therapeutics Market, by Disease Type (Neurodegenerative Disorders {Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, and Others}, Infectious Diseases, Psychotic Disorders, Anxiety Disorders, Trauma, Mood Disorders, and Others), by Drug Class (Analgesics, Anti-cholinergic Agents, Anticonvulsants, Sedatives and Hypnotics, Antidepressants, Antipsychotics, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

Central nervous system (CNS) disorders are some of the most prevalent yet poorly treated illnesses. Achieving sufficient blood-brain barrier (BBB) penetration is one of the biggest challenges in the development of therapeutics for CNS disorders. For instance, according to an article published by National Center for Biotechnology Information, in January 2005, more than 98% of small molecular drugs and almost 100% of larger molecular drugs are ineffective in treating CNS diseases considering that BBB strictly limits the delivery of therapeutic agents to their target site in the CNS. BBB helps to keep homeostasis in the cerebral microenvironment by controlling exchanges of substances between the CNS and the blood and serves an important function in preventing macromolecules, infectious substances, and potential neurotoxins from entering the brain. CNS disorders are rising due to factors such as aging, stress, and, lifestyle changes.

A limited understanding of the pathophysiology underlies that most of the psychiatric disorders such as schizophrenia, major depressive disorder, or bipolar disorder are only effective in a limited proportion of the patients. Some of the CNS disorders include neurodegenerative disorders such as Alzheimer’s disease and Parkinson’s disease along with various infectious diseases, psychiatric disorders, mental disorders, trauma, mood disorders, and others.

Market Dynamics

The key players are focusing on various growth strategies such as collaborations and agreements which is expected to drive the market growth during the forecast period. For instance, in July 2021, Eli Lilly and Company, an American pharmaceutical company and Banner Alzheimer's Institute announced a strategic research collaboration as part of the planned Phase 3, randomized, placebo-controlled study evaluating donanemab, a biological drug in trial to treat early symptoms of Alzheimer's disease in participants at risk for cognitive and functional decline related to Alzheimer's disease (TRAILBLAZER-ALZ 3). TRAILBLAZER-ALZ 3 will evaluate whether treatment with donanemab can slow the clinical progression of Alzheimer's disease in trial participants.

Key features of the study:

  • This report provides an in-depth analysis of the global central nervous system disorders therapeutics market , and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global central nervous system disorders therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Biogen Inc., Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., Novartis AG, AstraZeneca Plc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, AbbVie Inc., Glaxosmithkline plc., Otsuka Pharmaceutical Co., Ltd., Dr. Reddy's Laboratories Ltd., Cipla Inc., Lupin Ltd, and Glenmark Pharmaceuticals
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global central nervous system disorders therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global central nervous system disorders therapeutics market
Detailed Segmentation:
  • Global central nervous system disorders therapeutics market, By Disease Type:
  • Neurodegenerative Disorders
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Others
  • Infectious Diseases
  • Psychiatric Disorders
  • Anxiety Disorders
  • Trauma
  • Mood Disorders
  • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Drug Class:
  • Analgesics
  • Anti-cholinergic Agents
  • Anticonvulsants
  • Sedatives and Hypnotics
  • Antidepressants
  • Antipsychotics
  • Others
  • Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Global Central Nervous System Disorders Therapeutics Market, By Region:
  • North America
  • Disease Type
  • Neurodegenerative Disorders
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Others
  • Infectious Diseases
  • Psychiatric Disorders
  • Anxiety Disorders
  • Trauma
  • Mood Disorders
  • Others
  • Drug Class
  • Analgesics
  • Anti-cholinergic Agents
  • Anticonvulsants
  • Sedatives and Hypnotics
  • Antidepressants
  • Antipsychotics
  • Others
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • U.S.
  • Canada
  • Latin America
  • Disease Type
  • Neurodegenerative Disorders
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Others
  • Infectious Diseases
  • Psychiatric Disorders
  • Anxiety Disorders
  • Trauma
  • Mood Disorders
  • Others
  • Drug Class
  • Analgesics
  • Anti-cholinergic Agents
  • Anticonvulsants
  • Sedatives and Hypnotics
  • Antidepressants
  • Antipsychotics
  • Others
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
  • Disease Type
  • Neurodegenerative Disorders
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Others
  • Infectious Diseases
  • Psychiatric Disorders
  • Anxiety Disorders
  • Trauma
  • Mood Disorders
  • Others
  • Drug Class
  • Analgesics
  • Anti-cholinergic Agents
  • Anticonvulsants
  • Sedatives and Hypnotics
  • Antidepressants
  • Antipsychotics
  • Others
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Disease Type
  • Neurodegenerative Disorders
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Others
  • Infectious Diseases
  • Psychiatric Disorders
  • Anxiety Disorders
  • Trauma
  • Mood Disorders
  • Others
  • Drug Class
  • Analgesics
  • Anti-cholinergic Agents
  • Anticonvulsants
  • Sedatives and Hypnotics
  • Antidepressants
  • Antipsychotics
  • Others
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • Disease Type
  • Neurodegenerative Disorders
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Others
  • Infectious Diseases
  • Psychiatric Disorders
  • Anxiety Disorders
  • Trauma
  • Mood Disorders
  • Others
  • Drug Class
  • Analgesics
  • Anti-cholinergic Agents
  • Anticonvulsants
  • Sedatives and Hypnotics
  • Antidepressants
  • Antipsychotics
  • Others
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • Disease Type
  • Neurodegenerative Disorders
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Multiple Sclerosis
  • Others
  • Infectious Diseases
  • Psychiatric Disorders
  • Anxiety Disorders
  • Trauma
  • Mood Disorders
  • Others
  • Drug Class
  • Analgesics
  • Anti-cholinergic Agents
  • Anticonvulsants
  • Sedatives and Hypnotics
  • Antidepressants
  • Antipsychotics
  • Others
  • Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
  • Company Profiles
  • Biogen Inc.
  • Company Highlights
  • Products Portfolio
  • Key Highlights
  • Financial Performance
  • Strategies
  • Pfizer Inc.
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Novartis AG
  • AstraZeneca Plc.
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Glaxosmithkline plc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Cipla Inc.
  • Lupin Ltd
  • Glenmark Pharmaceuticals
“*” marked represents similar segmentation in other categories in the respective section.


1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Market Snapshot, By Disease Type
Market Snapshot, By Drug Class
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Drivers
Restraints
Opportunity
Impact Analysis
PEST Analysis
Regulatory Scenario
Market Trends
Key Developments
Pipeline Analysis
Regulatory Scenario
Epidemiology
Prescription Pattern and Prescribing Behavior
4. Global Central Nervous System Disorders Therapeutics Market– Impact of Coronavirus (COVID-19) Pandemic
Demand and Supply Analysis
Epidemiology
Government Initiatives
5. Global Central Nervous System Disorders Therapeutics Market, By Disease Type, 2017 – 2028, (US$ Mn)
Introduction
Market Share Analysis, 2021 and 2028 (%)
Y-o-Y Growth Analysis, 2018 – 2028
Segment Trends
Neurodegenerative Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Alzheimer’s Disease
Parkinson’s Disease
Multiple Sclerosis
Others
Infectious Diseases
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Psychiatric Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Anxiety Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Dry
Wet
Trauma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Mood Disorders
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
6. Global Central Nervous System Disorders Therapeutics Market, By Drug Class, 2017 – 2028, (US$ Mn)
Introduction
Market Share Analysis, 2021 and 2028 (%)
Y-o-Y Growth Analysis, 2018 – 2028
Segment Trends
Analgesics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
Anti-cholinergic Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
Anticonvulsants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Sedatives and Hypnotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Antidepressants
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Antipsychotics
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Mn)
7. Global Central Nervous System Disorders Therapeutics Market, By Distribution Channel, 2017 – 2028, (US$ Mn)
Introduction
Market Share Analysis, 2021 and 2028 (%)
Y-o-Y Growth Analysis, 2018 – 2028
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2017 – 2028, (US$ Million)
8. Global Central Nervous System Disorders Therapeutics Market, By Region, 2017 – 2028, (US$ Mn)
Introduction
Market Share Analysis, By Region, 2021 and 2028 (%)
Y-o-Y Growth Analysis, For Regions, 2017–2028
Regional Trends
North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
U.S.
Canada
Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
U.K.
Germany
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 – 2028, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 – 2028, (US$ Mn)
Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2017 – 2028, (US$ Mn)
North Africa
Central Africa
South Africa
9. Competitive Landscape
Heat Map Analysis
Market Share Analysis
Biogen Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Pfizer Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Eli Lilly and Company
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Merck & Co., Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Novartis AG
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
AstraZeneca Plc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Teva Pharmaceutical Industries Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Takeda Pharmaceutical Company Limited
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
AbbVie Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Glaxosmithkline plc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Otsuka Pharmaceutical Co., Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Dr. Reddy's Laboratories Ltd.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Cipla Inc.
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Lupin Ltd
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Glenmark Pharmaceuticals
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
Analyst Views
10. Section
Research Methodology
About us
*Browse 36 market data tables and 43 figures on "Central Nervous System Disorders Therapeutics Market” - Global forecast to 2028

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings